Grant: Alliance Grants
McMaster University
$100,000.00
Developing novel micro-needle patches for vaccine preservation and delivery
FY 2024-25
Summary
Since the COVID 19 pandemic, vaccine delivery using viral vectors have gained traction due to their ability to target adaptive immune cell responses, while bypassing innate immunity. In comparison, protein-based or live attenuated vaccines, require 10+ years to develop and test. Viral vector vaccines are currently delivered by injection via syringe, directly into muscle or skin tissue. Limitations arise for adoption in low-income communities, for example, as cold chain storage and health professional administration are required, making it highly demanding in cost and resources. Elarex has recently developed a low-cost alternative to cold-chain distribution, using pullulan and trehalose in their PT120-D technology, to trap viral vector vaccines for room temperature storage, which is lower incost and a more adaptable option for widespread distribution. This project, led by the McMaster team at the Didar Lab, seeks to leverage Elarex's stabilization technology to re-design vaccine delivery methods from injection, administered by a healthcare professional, to self-administrable micro-array patches (MAPs). Microneedles will be developed from sustainable polymers on a patch, with viral vectors encapsulated, only releasing after penetration with the skin. Once tested using adenovirus (AdV) and vesicular stomatitis virus (VSV) vectors in skin and mouse models are complete, Elarex plans to expand the results of this project to other vaccine vector platforms, to make a universal vaccine-loaded MAPs design, as well as test vaccine efficacy and toxicity in preclinical and clinical trials. Within 5 years, Elarex plans to establish a streamlined distribution pipeline for commercial vaccine-loaded MAPs, to reduce economic and healthcare burdens of vaccine delivery in Canada and globally.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
597199-2024
Name nom
Didar, Tohid TFD
Department département
Mechanical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
100000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
2006
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Biomaterials
Research subject fr
Biomatériaux
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Developing novel micro-needle patches for vaccine preservation and delivery
Keywords
biomaterials; dissolvable microneedles; intradermal delivery; micro-array patches; microfabrication; micromolding; vaccine delivery; vaccine efficacy; vaccine stabilization; viral vector vaccines
Application summary
Since the COVID 19 pandemic, vaccine delivery using viral vectors have gained traction due to their ability to target adaptive immune cell responses, while bypassing innate immunity. In comparison, protein-based or live attenuated vaccines, require 10+ years to develop and test. Viral vector vaccines are currently delivered by injection via syringe, directly into muscle or skin tissue. Limitations arise for adoption in low-income communities, for example, as cold chain storage and health professional administration are required, making it highly demanding in cost and resources. Elarex has recently developed a low-cost alternative to cold-chain distribution, using pullulan and trehalose in their PT120-D technology, to trap viral vector vaccines for room temperature storage, which is lower incost and a more adaptable option for widespread distribution. This project, led by the McMaster team at the Didar Lab, seeks to leverage Elarex's stabilization technology to re-design vaccine delivery methods from injection, administered by a healthcare professional, to self-administrable micro-array patches (MAPs). Microneedles will be developed from sustainable polymers on a patch, with viral vectors encapsulated, only releasing after penetration with the skin. Once tested using adenovirus (AdV) and vesicular stomatitis virus (VSV) vectors in skin and mouse models are complete, Elarex plans to expand the results of this project to other vaccine vector platforms, to make a universal vaccine-loaded MAPs design, as well as test vaccine efficacy and toxicity in preclinical and clinical trials. Within 5 years, Elarex plans to establish a streamlined distribution pipeline for commercial vaccine-loaded MAPs, to reduce economic and healthcare burdens of vaccine delivery in Canada and globally.